Advertisement

Medical Oncology

, Volume 29, Issue 3, pp 2046–2052 | Cite as

Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia

  • Mina Fathi
  • Zahra Amirghofran
  • Mehdi Shahriari
Original Paper

Abstract

The soluble forms of Fas and its ligand (sFas and sFasL) correlate with disease progression in various malignancies. We compared serum levels of sFas and sFasL in children with acute lymphoblastic leukemia and healthy children to determine the prognostic significance of these molecules. Serum levels of sFas and sFasL were measured with an enzyme-linked immunosorbent assay in 48 patients with newly diagnosed childhood acute lymphoblastic leukemia and 38 healthy children. Cut-off values of sFas and sFasL levels were based on their levels in controls. Clinical and laboratory characteristics were recorded on admission. The mean serum concentration of sFas was 243 ± 40 pg/mL in patients and 238 ± 29 pg/mL in controls. Serum levels of sFasL were 4.33 ± 0.25 ng/mL in patients and 4.27 ± 0.11 ng/mL in controls. Neither difference was significant. Based on the cut-off value, 12.5% of the patients were positive for sFas, and 16.6% were positive for sFasL. Survival was significantly longer in sFasL-positive patients (394 ± 69.6 vs. 254 ± 24.3 days) and the duration of complete remission was also longer (380 ± 65.0 vs. 246 ± 26.0 days) than in sFasL-negative patients (P < 0.02), indicating the important role of this molecule in the response to therapy. Higher sFas levels were associated with hepatosplenomegaly (P < 0.047). In conclusion, sFasL positivity was associated with a favorable outcome in ALL patients.

Keywords

Fas Fas ligand Acute lymphoblastic leukemia Childhood Prognosis 

Notes

Acknowledgments

This work was supported by grant no. 4724 from Shiraz University of Medical Sciences. We thank Saied Malek Hoseini and the head nurses of the pediatric oncology ward of Amir Hospital in Shiraz for help with liaising with the patients, K. Shashok (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript, and M. Gholami at the Center for Development of Clinical Research of Nemazee Hospital for research assistance.

Conflict of interest

None.

References

  1. 1.
    Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:655–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am. 2009;23:1033–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Whitlock JA, Gaynon PS. Acute lymphoblastic leukemia in children. In: Greer JP, Foerster J, Lukens JN, editors. Wintrobe’s Clinical Hematology, 11th ed. 11th ed. Philadelphia: Lippincott Williams & Wilkins, Lippincott; 2003. p. 4298–354.Google Scholar
  4. 4.
    Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Pieters R. Acute lymphoblastic leukemia in children and adolescents: chance of cure now higher than 80%. Ned Tijdschr Geneeskd. 2010;154:A1577.PubMedGoogle Scholar
  6. 6.
    Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150:389–405.PubMedGoogle Scholar
  7. 7.
    Iannolo G, Conticello C, Memeo L, et al. Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol. 2008;66:42–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001;92:57–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Guicciardi ME, Gores GJ. Life and death by death receptors. Faseb J. 2009;23:1625–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci. 2005;11:265–7.CrossRefGoogle Scholar
  11. 11.
    Peter ME, Krammer PH. The CD95 (APO–1/Fas) disc and beyond. Cell Death Differ. 2003;10:26–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7:532–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2002;21:485–95.CrossRefGoogle Scholar
  14. 14.
    Igney FH, Krammer PH. Death and anti–death, tumor resistance to apoptosis. Nature Rev Cancer. 2002;2:277–88.CrossRefGoogle Scholar
  15. 15.
    Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol. 2002;12:309–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Yang J, Epling-Burnette PK, Painter JS, et al. Antigen activation and impaired Fas–induced death–inducing signaling complex formation in T–large–granular lymphocyte leukemia. Blood. 2008;111:1610–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T–regulatory cell homeostasis and suppression apoptosis in T–regulatory cell homeostasis. Immunol Cell Biol. 2008;86:650–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Urbaniank KD, Jazwies B, Tomaszewska TB, et al. Expression of Fas receptor and sFasL concentration in acute leukemia. Pol Arch Wewn. 2002;108:873–8.Google Scholar
  19. 19.
    Liu X, Qi Z, Luo L, Zhang X (1999) Measurement of soluble Fas in patients with hematological malignancy. Hunan Yi Ke Da Xue Xue Bao 24:171–173, 176.Google Scholar
  20. 20.
    Kapplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  21. 21.
    Schimmer AD. Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract Res Clin Haematol. 2008;21:5–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Jattela M. Multiple cell death pathways are regulators of tumor initiation and progression. Oncogene. 2004;23:2746–56.CrossRefGoogle Scholar
  23. 23.
    Krueger A, Fas SC, Baumann S, et al. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev. 2003;193:58–69.PubMedCrossRefGoogle Scholar
  24. 24.
    Amirghofran Z, Bahmani M, Azadmehr A, et al. Anticancer effects of various Iranian native medicinal plants on human tumor cell lines. Neoplasma. 2006;53:428–33.PubMedGoogle Scholar
  25. 25.
    Amirghofran Z, Daneshbod Y, Gholijani N. Bcl–2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res. 2009;17:447–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol. 2003;15:145–57.PubMedCrossRefGoogle Scholar
  27. 27.
    Barnhart BC, Legembre P, Pietras E, et al. CD95 ligand induces motility and invasiveness of apoptosis–resistant tumor cells. EMBO J. 2004;23:3175–85.PubMedCrossRefGoogle Scholar
  28. 28.
    Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance. Oncogene. 2004;23:2934–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Mata JF, Silveira VS, Mateo EC, et al. Low mRNA expression of the apoptosis–related genes CASP3, CASP8, and Fas is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2010;55:100–7.PubMedGoogle Scholar
  30. 30.
    Li Q, Tsuruda K, Sugahara KN, et al. Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells. Leuk Res. 2000;24:437–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Vries EG, Timmer T, Mulder NH, et al. Modulation of death receptor pathways in oncology. Drugs Today (Barc). 2003;39(Suppl):95–109.Google Scholar
  32. 32.
    Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl–2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukemia. Br J Hematol. 2000;110:154–60.CrossRefGoogle Scholar
  33. 33.
    Min YH, Lee S, Lee JW, et al. Expression of Fas antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy. Br J Hematol. 1996;93:928–30.CrossRefGoogle Scholar
  34. 34.
    Hentschel N, Krusch M, Kiener PA, et al. Serum levels of sCD137 (4–1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin’s lymphoma. Eur J Haematol. 2006;77:91–101.PubMedCrossRefGoogle Scholar
  35. 35.
    Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer. 2005;113:78–87.PubMedCrossRefGoogle Scholar
  36. 36.
    Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000;191:1209–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Pearl-Yafe M, Yolcu ES, Yaniv I, et al. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays. 2006;28:211–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Abbasova SG, Vysotskii MM, Ovchinnikova LK. Cancer and soluble Fas. Bull Exp Biol Med. 2009;148:638–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Osorio LM, Aguilar-Santelises M, De Santiago A, et al. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol. 2001;66:342–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Ebeid EN, Khairy A, Amin M, et al. Soluble CD95 (APO–1/Fas) level in infancy and childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(suppl):8540.Google Scholar
  42. 42.
    Hazar V, Berber Z, Pestereli E, et al. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Pediatr Hematol Oncol. 2005;22:247–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Courtney PA, Crockard AD, Williamson K, et al. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus. 1999;8:508–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Herrmann M, Voll RE, Zoller OM, et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1241–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Mina Fathi
    • 1
  • Zahra Amirghofran
    • 1
  • Mehdi Shahriari
    • 2
  1. 1.Department of Immunology, Shiraz Medical School, Medicinal and Natural Products Chemistry Research Center and Autoimmune Diseases Research CenterShiraz University of Medical SciencesShirazIran
  2. 2.Department of PediatricsShiraz University of Medical SciencesShirazIran

Personalised recommendations